Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India

Insulin maker GeneSys to invest $50-60 mn to set up plant in Hyderabad

 Biotechnology company GeneSys Biologics Pvt Ltd is planning to invest USD 50-60 million to set up a new large-scale recombinant bulk manufacturing facility in Genome Valley here for the production of insulin analogues. The insulin analogues (medical insulin that are altered forms of the human hormone insulin) will be produced in the recombinant bulk manufacturing facility in which purified bulk insulin will be derived through fermentation. An official press release said the Hyderabad-based company has already invested approximately USD 50 million in its Genome Valley plant. Telangana IT and Industries Minister K T Rama Rao expressed delight over the expansion plans of GeneSys saying it will not only contribute to the growth of Hyderabad's biotech sector but also facilitate the company's ongoing collaboration with US-based Civica Rx. GeneSys has partnered with Civica Rx, a US non-profit generic drug company, to manufacture and distribute affordable insulin. The minister congratulat
19-05-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 The Nomination and Remuneration Committee at its meeting held on May 08, 2023 has approved the allotment of 18,815 equity shares of face value of Rs. 5/- each pursuant to the exercise of the Stock Options by the eligible employees of the company under the Genesys ESOP Scheme -2020. Consequently, post-allotment the paid-up capital of the company shall stand increased to Rs.18,88,69,570/- divided into 3,77,73,914 equity shares of face value of Rs. 5/- each. These shares shall rank pari passu with the existing equity shares of the Company in all respects.
08-05-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Year Ended March 2023.

 Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the Compliance Certificate for the year ended on March 31, 2023.
25-04-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGENESYS INTERNATIONAL CORPORATION LTD. 2CIN NO.L65990MH1983PLC029197 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 17.34 4Highest Credit Rating during the previous FY BBB 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Vineet Chopra Designation: Vice President Legal and Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Vishnubhatla Ravi Kumar Jatavallabha Designation: Chief Financial Officer EmailId: [email protected] Date: 25/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
25-04-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Filing Of Compliance Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2023.

 Pursuant to Regulation 40(9) read with Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Compliance Certificate for the year ended on March 31, 2023 issued by Roy Jacob & Co., Company Secretaries, the copy of which will be placed before the ensuing meeting of the Board of Directors of the Company.
20-04-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In Compliance with the Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we are enclosing herewith the certificate received from M/s. Bigshare Services Private Limited the Registrar and Share Transfer Agent of the Company for the quarter ended March 31, 2023.
11-04-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Closure of Trading Window

 This is to inform you that as per the Company's Code of Conduct framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company shall remain closed for all Designated Persons and their immediate relatives from April 01, 2023 till the expiry of 48 hours after the declaration of financial results of the Company for the quarter and year ended March 31, 2023.
31-03-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 The Compensation Committee at its meeting held on March 17, 2023 has approved the allotment of 33,975 equity shares of face value of Rs. 5/- each pursuant to the exercise of the Stock Options by the eligible employees of the company under the Genesys ESOP Scheme -2020 and Genesys ESOP Scheme - 2010. Consequently, post-allotment the paid-up capital of the company shall stand increased to Rs.188,775,495.00 /- divided into 37,755,099 equity shares of face value of Rs. 5/- each. These shares shall rank pari passu with the existing equity shares of the Company in all respects.
17-03-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 In compliance with Regulation 39 (3) of Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 and as informed by the Registrar and Share Transfer Agent, intimation is hereby given regarding loss of share certificate(s) and issue of duplicate share certificate as per attachment.
24-02-2023
Bigul

GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 We are enclosing herewith the copy of Standalone and Consolidated un-audited financial results of the Company for the quarter and nine months ended December 31, 2022, as published in the Newspaper - The Free Press Journal (English) and Navshakti (Marathi) on Thursday, February 16, 2023
16-02-2023
Next Page
Close

Let's Open Free Demat Account